Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (111-120 of 457) with videos related to

Pageof 46
Sort By:
Advances in Therapy|May 30, 2026
Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM SurveyTimothy Arnaut, Shannon Duncan, Mads Faurby, et al.
Advanced Materials (Deerfield Beach, Fla.)|April 24, 2016
Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (Adv. Mater. 16/2016)Yanqi Ye, Jicheng Yu, Chao Wang, et al.
Diabetes Care|June 17, 2015
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 InhibitionAnne L Peters, Elizabeth O Buschur, John B Buse, et al.
Lancet (London, England)|September 11, 2008
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyDaniel J Drucker, John B Buse, Kristin Taylor, et al.
Human Genomics|June 22, 2024
Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank populationCourtney Hershberger, Arshiya Mariam, Kevin M Pantalone, et al.
Diabetes, Obesity & Metabolism|February 15, 2017
No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternativesMugdha Gokhale, John B Buse, Michele Jonsson Funk, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER TrialBernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
BMJ Open Diabetes Research & Care|October 15, 2025
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trialJohn B Buse, Helene Nordahl Christensen, Brian J Harty, et al.
The American Journal of Cardiology|April 9, 2018
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)Steven P Marso, Michael A Nauck, Tea Monk Fries, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 2, 2016
Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin DeliveryYanqi Ye, Jicheng Yu, Chao Wang, et al.
Pageof 46

Showing results (111-120 of 457) with videos related to

Sort By:
Pageof 46
Advances in Therapy|May 30, 2026
Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM SurveyTimothy Arnaut, Shannon Duncan, Mads Faurby, et al.
Advanced Materials (Deerfield Beach, Fla.)|April 24, 2016
Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (Adv. Mater. 16/2016)Yanqi Ye, Jicheng Yu, Chao Wang, et al.
Diabetes Care|June 17, 2015
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 InhibitionAnne L Peters, Elizabeth O Buschur, John B Buse, et al.
Lancet (London, England)|September 11, 2008
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyDaniel J Drucker, John B Buse, Kristin Taylor, et al.
Human Genomics|June 22, 2024
Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank populationCourtney Hershberger, Arshiya Mariam, Kevin M Pantalone, et al.
Diabetes, Obesity & Metabolism|February 15, 2017
No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternativesMugdha Gokhale, John B Buse, Michele Jonsson Funk, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER TrialBernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
BMJ Open Diabetes Research & Care|October 15, 2025
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trialJohn B Buse, Helene Nordahl Christensen, Brian J Harty, et al.
The American Journal of Cardiology|April 9, 2018
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)Steven P Marso, Michael A Nauck, Tea Monk Fries, et al.
Advanced Materials (Deerfield Beach, Fla.)|March 2, 2016
Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin DeliveryYanqi Ye, Jicheng Yu, Chao Wang, et al.
Pageof 46